Predicting Dietary Selenium Needs to Achieve Target Blood Selenium Levels
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Nutritional Requirements
- Sponsor
- USDA Grand Forks Human Nutrition Research Center
- Enrollment
- 262
- Locations
- 1
- Primary Endpoint
- Evaluation of effectiveness of consuming oral doses of L-selenomethionine in raising plasma selenium concentrations
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
In this study, we will evaluate the effectiveness of several doses of oral selenomethionine in raising biomarkers of selenium status including plasma selenium concentrations.
Detailed Description
Results of studies with animal tumor models and human clinical trials suggest that the essential nutrient selenium can be anti-tumorigenic if consumed at levels greater than nutritional requirements. If it is possible to increase plasma selenium concentrations above 120 nanograms per milliliter with less than 200 micrograms of selenium daily, then it is possible that supplementation can be accomplished through the use of selenium-containing foods.
Investigators
Eligibility Criteria
Inclusion Criteria
- •able to swallow capsules
- •body mass index less than 40
Exclusion Criteria
- •Pregnancy
- •Chronic liver or kidney disease
- •taking medication that might affect liver and/or kidney
- •blood pressure 140/90 or higher
- •already taking more than 50 micrograms of selenium
Outcomes
Primary Outcomes
Evaluation of effectiveness of consuming oral doses of L-selenomethionine in raising plasma selenium concentrations
Time Frame: Baseline, and after 3, 6, 9, and 12 months of supplementation
Secondary Outcomes
- Biomarkers of selenium status will be determined in urine, buccal cells, and plasma. White blood cells will be analyzed to identify DNA damage, reflecting the degree of oxidative damage and evaluate the status of antioxidant repair mechanisms.(Baseline and after 12 months of supplementation)